A new formulation for protein therapies could transform these treatments from something requiring a slow intravenous infusion to something patients could self-administer in seconds at home.
The formulation stabilizes the proteins and prevents them from aggregating, enabling higher-concentration medications. The stabilization may also allow the medications to be stored at room temperature, which would make them more accessible for people worldwide.
“This could be used with any kind of protein drug,” says Eric Appel, an associate professor of materials science and engineering at Stanford Univ. and the senior author of a new paper in the journal Science Translational Medicine describing the formulation. Protein therapies are used to treat a variety of illnesses, from infectious diseases like COVID-19 to bleeding disorders like thrombocytopenia to autoimmune disorders and cancer.
It’s difficult to pack high concentrations of proteins into a formulation without the medication becoming viscous or the proteins clumping. That means proteins have to be delivered in large...
Would you like to access the complete CEP News Update?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
-
Log in
You must be logged in to view this content. Log in now.
-
AIChE Membership
You must be an AIChE member to view this article. Join now.
Copyright Permissions
Would you like to reuse content from CEP Magazine? It’s easy to request permission to reuse content. Simply click here to connect instantly to licensing services, where you can choose from a list of options regarding how you would like to reuse the desired content and complete the transaction.
